Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TTR | P02766 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4854035 | 1.00 | MEN1 (0.60) | MEN1ALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL4845752 | 0.80 | PTPN1 (0.56) | MEN1ALDH1A1KMT2APTPN1 | |
| SCHEMBL4845761 | 0.80 | PTPN1 (0.56) | MEN1ALDH1A1KMT2APTPN1 | |
| SCHEMBL23036942 | 0.78 | MTOR (0.59) | ALDH1A1KDM4ETTRPTGS2 | |
| SCHEMBL13345210 | 0.78 | PLK1 (0.65) | MEN1KMT2APOLBHTTHPGD | |
| SCHEMBL716851 | 0.76 | PTGS2 (0.52) | MEN1ALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL12155710 | 0.76 | MEN1 (1.00) | MEN1ALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL1247460 | 0.76 | MEN1 (1.00) | MEN1ALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL1247458 | 0.76 | MEN1 (1.00) | MEN1ALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL3393009 | 0.76 | MTOR (0.56) | TTRPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368578-B2 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060135578-A1 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135578-A1 | Five-membered heterocyclic compounds | GPR119, OR10J3, CYP11B1 | MEN1 3268/4885ALDH1A1 821/4885KMT2A 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.